Hims & Hers Health, Inc. (NYSE:HIMS) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lifted its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 48.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,248 shares of the company's stock after acquiring an additional 5,655 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in Hims & Hers Health were worth $536,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the business. Blume Capital Management Inc. raised its holdings in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company's stock valued at $29,000 after purchasing an additional 600 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in Hims & Hers Health by 4,415.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company's stock worth $36,000 after buying an additional 1,413 shares in the last quarter. Summit Securities Group LLC bought a new position in Hims & Hers Health in the fourth quarter worth approximately $38,000. UMB Bank n.a. lifted its stake in shares of Hims & Hers Health by 247.5% during the 1st quarter. UMB Bank n.a. now owns 1,310 shares of the company's stock worth $39,000 after purchasing an additional 933 shares during the last quarter. Finally, Fifth Third Bancorp boosted its holdings in shares of Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after buying an additional 961 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms recently commented on HIMS. Wall Street Zen upgraded shares of Hims & Hers Health from a "hold" rating to a "buy" rating in a research note on Sunday, June 15th. Morgan Stanley reaffirmed an "equal weight" rating and set a $40.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, June 11th. UBS Group set a $30.00 target price on Hims & Hers Health in a research note on Monday, June 23rd. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Finally, Piper Sandler reiterated a "neutral" rating and set a $39.00 price objective (up previously from $35.00) on shares of Hims & Hers Health in a research report on Tuesday, May 6th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $39.58.

Insider Buying and Selling

In related news, insider Soleil Boughton sold 2,572 shares of Hims & Hers Health stock in a transaction that occurred on Monday, June 30th. The shares were sold at an average price of $50.50, for a total value of $129,886.00. Following the completion of the transaction, the insider owned 160,737 shares in the company, valued at $8,117,218.50. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Irene Becklund sold 8,485 shares of the firm's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total transaction of $506,978.75. Following the completion of the sale, the insider owned 712 shares in the company, valued at $42,542. The trade was a 92.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 670,250 shares of company stock worth $34,487,591 over the last ninety days. Company insiders own 13.71% of the company's stock.

Hims & Hers Health Trading Down 2.0%

HIMS traded down $1.01 during mid-day trading on Thursday, hitting $50.23. 21,261,404 shares of the stock were exchanged, compared to its average volume of 23,713,398. Hims & Hers Health, Inc. has a 1-year low of $13.47 and a 1-year high of $72.98. The firm's fifty day moving average is $53.26 and its two-hundred day moving average is $40.67. The company has a market cap of $11.24 billion, a PE ratio of 72.80, a PEG ratio of 1.80 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The business had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a net margin of 9.24% and a return on equity of 22.75%. The company's quarterly revenue was up 110.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.05 earnings per share. As a group, research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.